

FCAR Antibody (Center) Blocking peptide
Synthetic peptide
Catalog # BP12915c**Specification**

FCAR Antibody (Center) Blocking peptide - Product InformationPrimary Accession [P24071](#)**FCAR Antibody (Center) Blocking peptide - Additional Information****Gene ID** 2204**Other Names**

Immunoglobulin alpha Fc receptor, IgA Fc receptor, CD89, FCAR, CD89

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

FCAR Antibody (Center) Blocking peptide - Protein Information**Name** FCAR**Synonyms** CD89**Function**

Binds to the Fc region of immunoglobulins alpha. Mediates several functions including cytokine production.

Cellular Location

[Isoform A.1]: Cell membrane; Single-pass type I membrane protein [Isoform A.3]: Cell membrane; Single-pass type I membrane protein [Isoform B-delta-S2]: Secreted.

Tissue Location

Isoform A.1, isoform A.2 and isoform A.3 are differentially expressed between blood and mucosal myeloid cells Isoform A.1, isoform A.2 and isoform A.3 are expressed in monocytes Isoform A.1 and isoform A.2 are expressed in alveolar macrophages; however only one isoform is expressed at alveolar macrophages surfaces

FCAR Antibody (Center) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

FCAR Antibody (Center) Blocking peptide - Images

FCAR Antibody (Center) Blocking peptide - Background

This gene is a member of the immunoglobulin genesuperfamily and encodes a receptor for the Fc region of IgA. Thereceptor is a transmembrane glycoprotein present on the surface ofmyeloid lineage cells such as neutrophils, monocytes, macrophages,and eosinophils, where it mediates immunologic responses to pathogens. It interacts with IgA-opsonized targets and triggersseveral immunologic defense processes, including phagocytosis,antibody-dependent cell-mediated cytotoxicity, and stimulation ofthe release of inflammatory mediators. Multiple alternativelyspliced transcript variants encoding different isoforms have beendescribed for this gene.

FCAR Antibody (Center) Blocking peptide - References

Vuong, M.T., et al. Kidney Int. (2010) In press :Davila, S., et al. Genes Immun. 11(3):232-238(2010)Peng, M., et al. Cell Res. 20(2):223-237(2010)Kobayashi, T., et al. J. Dent. Res. 88(12):1137-1141(2009)van der Steen, L., et al. Gastroenterology 137(6):2018-2029(2009)